Hematological Issues in Liver Disease

Critical Care Clinics

Volumn 32, Issue 3, 2016, Pages 385-396

  Allison, Michael G ^a   Shanholtz, Carl B ^b   Sachdeva, Ashutosh ^b  

^a ST AGNES HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acute liver failure; Anticoagulation; Cirrhosis; Coagulopathy; Thrombocytopenia; Thrombosis

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR; ENOXAPARIN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT;

ACUTE LIVER FAILURE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; DISSEMINATED INTRAVASCULAR CLOTTING; ESOPHAGUS VARICES; FIBRINOLYSIS; HEMATOLOGIC DISEASE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; PARTIAL THROMBOPLASTIN TIME; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; THROMBOSIS PREVENTION; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD COAGULATION DISORDERS; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; HEMORRHAGE; PATHOPHYSIOLOGY; THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; DISSEMINATED INTRAVASCULAR COAGULATION; HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE, ACUTE; THROMBOSIS;

EID: 84974816108     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2016.03.004     Document Type: Review

References (58)

1. Lisman T., Porte R.J. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010, 116:878-885.
2. Tripodi A., Salerno F., Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005, 41:553-558.
3. Tripodi A., Primignani M., Chantarangkul V., et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006, 44:440-445.
4. Tripodi A., Primignani M., Chantarangkul V., et al. An imbalance of pro- vs. anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009, 137:2105-2111.
5. Hollestelle M.J., Geertzen H.G., Straatsberg I.H., et al. Factor VIII expression in liver disease. Thromb Haemost 2004, 91:267-275.
6. Dultz G., Kronenberger B., Azizi A., et al. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011, 55:229-232.
7. Afdhal N.H., Giannini E.G., Tayyab G., et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012, 367:716-724.
8. Thomas D.P., Ream V.J., Stuart P.K. Platelet aggregation in patients with Laennac's cirrhosis of the liver. N Engl J Med 1967, 276:1344-1348.
9. Violi F., Leo R., Vezza E., et al. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. group. Coagulation abnormalities in cirrhosis study group. J Hepatol 1994, 20:531-536.
10. Mannucci P.M., Canciani M.T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001, 98:2730-2735.
11. Lisman T., Bongers T.N., Adelmeijer J., et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006, 44:53-61.
12. Goodpasture E.W. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp 1914, 25:330-332.
13. Colucci M., Binetti B.M., Branca M.G., et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003, 38:230-237.
14. Papatheodoridis G.V., Patch D., Webster G.J.M., et al. Infection and hemostasis in decompensated cirrhosis: a prospective study using thromboelastography. Hepatology 1999, 29:1085-1090.
15. Lisman T., Bakhtari K., Adelmeijer J., et al. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012, 10:1312-1319.
16. Caldwell S.H., Hoffman M., Lisman T., et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006, 44:1039-1046.
17. Kang Y.G., Martin D.J., Marquez J., et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg 1985, 64:888-896.
18. Stravitz R.T., Lisman T., Luketic V.A., et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012, 56:129-136.
19. Stravitz R.T. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol (N Y) 2012, 8:513-520.
20. Tripodi A., Primignani M., Chantarangkul V., et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009, 124:132-136.
21. Chau T.N., Chan Y.W., Patch D., et al. Thromboelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998, 43:267-271.
22. Sharara A.I., Rockey D.C. Gastroesophageal variceal hemorrhage. N Engl J Med 2001, 345:669-681.
23. Shah N.L., Northup P.G., Caldwell S.H. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol 2012, 11:686.
24. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981, 26:388.
25. Gilmore I.T., Burroughs A., Murray-Lyon I.M., et al. Indications, methods and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995, 36:437-441.
26. Denzer U., Helmreich-Becker I., Galle P.R., et al. Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding. Am J Gastroenterol 2003, 98:893-900.
27. Segal J.B., Dzik W.H., Transfusion Medicine/Hemostasis Clinical Trials Network Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005, 45:1413-1425.
28. Grabau C.M., Crago S.F., Hoff L.K., et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004, 40:484-488.
29. Townsend J.C., Heard R., Powers E.R., et al. Usefulness of international normalized ratio to predict bleeding complications in patients with end-stage liver disease who undergo cardiac catheterization. Am J Cardiol 2012, 110:1062-1065.
30. Joist J.H. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999, 94(10):2801-2803.
31. Tripodi A., Primignani M., Lemma L., et al. Detection of the imbalance of pro-coagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010, 52:249-255.
32. Kolisak L.P., Maynor L. Pharmacologic prophylaxis against venous thromboembolism in hospitalized patients with cirrhosis and associated coagulopathies. Am J Health Syst Pharm 2012, 69:658-663.
33. Okuda K., Ohnishi K., Kimura K., et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985, 89(2):279-286.
34. Francoz C., Belghiti J., Vilgrain V., et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005, 54:691-697.
35. Nery F., Chevret S., Condat B., et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015, 61:660-667.
36. Sogaard K.K., Horvath-Puho E., Grobaek H., et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009, 104:96-101.
37. Ali M., Ananthakrishnan A.N., McGinley E.L., et al. Deep venous thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci 2011, 52:2152-2159.
38. Northup P.G., McMahon M.M., Ruhl A.P., et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006, 101:1524-1528.
39. Gulley D., Teal E., Suvannasankha A., et al. Deep venous thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008, 53:3012-3017.
40. Walsh K.A., Lewis D.A., Clifford T.M., et al. Risk factors for venous thromboembolism in patients with chronic liver disease. Ann Pharmacother 2013, 47(3):333-339.
41. Lizarraga W.A., Dalia S., Reinert S.E., et al. Venous thrombosis in patients with chronic liver disease. Blood Coagul Fibrinolysis 2010, 21:431-435.
42. Dabbagh O., Oza A., Prakash S., et al. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010, 137:1145-1149.
43. Afdhal N., McHutchinson J., Brown R., et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008, 48(6):1000-1007.
44. Kahn S.R., Lim W., Dunn A.S., et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e195S-e226S.
45. Stanworth S.J. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and coagulopathy. Hematology Am Soc Hematol Educ Program 2007, 179-186.
46. Kirchner C., Goerlinger K., Dirkmann D., et al. Safety and efficacy of prothrombin complex and fibrinogen concentrates in liver transplantation. Liver Transplant 2012, 18:S189.
47. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 2009, 49:1017-1044.
48. Clayton D.G., Miro A.M., Kramer D.J., et al. Quantification of thromboelastographic changes after blood component transfusion in patients with liver disease in the intensive care unit. Anesth Analg 1995, 81:272-278.
49. Sharma P., McDonald G.B., Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982, 4:451-453.
50. Bennett C., Klingenberg S., Langholz E., et al. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2014, (11). CD006640.
51. Molenaar I.Q., Warnaar N., Groen H., et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007, 7:185-194.
52. Arshad F., Ickx B., van Beem R.T., et al. Prothrombin complex concentrate in the reduction of blood loss during orthotropic liver transplantation: PROTON-trial. BMC Surg 2013, 13:1-12.
53. Condat B., Pessione F., Denninger M.H., et al. Recent portal or mesenteric thrombosis: increased recognition and frequent recanalization on anticoagulation therapy. Hepatology 2000, 32:466-470.
54. DeLeve L.D., Valla D.C., Garcia-Tsao G., et al. Vascular disorders of the liver. Hepatology 2009, 49:1729-1764.
55. Kearon C., Akl E.A., Comerota A.J., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e419S-e494S.
56. Amitrano L., Guardascione M.A., Menchise A., et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010, 44:448-451.
57. Delgado M.G., Seijo S., Yepes I., et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012, 10:776-783.
58. Cui S.B., Shu R.H., Yan S.P., et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol 2015, 27:914-919.